164
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii Isolates Among Intensive Care Unit Patients and Environment

ORCID Icon, , , , , , , , , , & show all
Pages 1821-1829 | Published online: 13 Apr 2022

References

  • Ripabelli G, Sammarco ML, Scutella M, Felice V, Tamburro M. Carbapenem-resistant kpc- and tem-producing Escherichia coli st131 isolated from a hospitalized patient with urinary tract infection: first isolation in Molise region, central Italy, July 2018. Microb Drug Resist. 2020;26(1):38–45. doi:10.1089/mdr.2019.0085
  • Sarshar M, Behzadi P, Scribano D, Palamara AT, Ambrosi C. Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens. 2021;10(4):387. doi:10.3390/pathogens10040387
  • Hu H, Zhang Y, Zhang P, et al. Bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing p. Aeruginosa sequence type 463, associated with high mortality rates in China: a retrospective cohort study. Front Cell Infect Microbiol. 2021;11:756782. doi:10.3389/fcimb.2021.756782
  • Ahmadi M, Ranjbar R, Behzadi P, Mohammadian T. Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella pneumoniae. Expert Rev Anti Infect Ther. 2021;20(3):463–472. doi:10.1080/14787210.2022.1990040
  • Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960. doi:10.1128/AAC.00296-11
  • Nguyen M, Joshi SG. Carbapenem resistance in acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. J Appl Microbiol. 2021;131(6):2715–2738. doi:10.1111/jam.15130
  • Behzadi P, Garcia-Perdomo HA, Karpinski TM, Issakhanian L. Metallo-ss-lactamases: a review. Mol Biol Rep. 2020;47(8):6281–6294. doi:10.1007/s11033-020-05651-9
  • Reyes J, Aguilar AC, Caicedo A. Carbapenem-resistant Klebsiella pneumoniae: microbiology key points for clinical practice. Int J Gen Med. 2019;12:437–446. doi:10.2147/IJGM.S214305
  • Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–272. doi:10.1016/j.molmed.2012.03.003
  • Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–1106. doi:10.1086/592412
  • Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582. doi:10.1128/CMR.00058-07
  • Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423. doi:10.1111/1469-0691.12363
  • Catho G, Martischang R, Boroli F, et al. Outbreak of pseudomonas aeruginosa producing vim carbapenemase in an intensive care unit and its termination by implementation of waterless patient care. Crit Care. 2021;25(1):301. doi:10.1186/s13054-021-03726-y
  • Wei L, Wu L, Wen H, et al. Spread of carbapenem-resistant Klebsiella pneumoniae in an intensive care unit: a whole-genome sequence-based prospective observational study. Microbiol Spectr. 2021;9(1):e0005821. doi:10.1128/Spectrum.00058-21
  • Kim DH, Jung SI, Kwon KT, Ko KS. Occurrence of diverse abgri1-type genomic islands in acinetobacter baumannii global clone 2 isolates from South Korea. Antimicrob Agents Chemother. 2017;61(2). doi:10.1128/AAC.01972-16
  • CLSI. Performance standards for antimicrobial susceptibility testing. 30th. In: CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020
  • Hu H, Mao J, Chen Y, et al. Clinical and microbiological characteristics of community-onset carbapenem-resistant Enterobacteriaceae isolates. Infect Drug Resist. 2020;13:3131–3143. doi:10.2147/IDR.S260804
  • Seifert H, Dolzani L, Bressan R, et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of acinetobacter baumannii. J Clin Microbiol. 2005;43(9):4328–4335. doi:10.1128/JCM.43.9.4328-4335.2005
  • Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus acinetobacter). J Bacteriol. 1968;95(5):1520–1541. doi:10.1128/jb.95.5.1520-1541.1968
  • Lee CR, Lee JH, Park M, et al. Biology of acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55. doi:10.3389/fcimb.2017.00055
  • Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant acinetobacter baumannii and Enterobacteriaceae in south and Southeast Asia. Clin Microbiol Rev. 2017;30(1):1–22. doi:10.1128/CMR.masthead.30-1
  • Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the who priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
  • Bernards AT, Frenay HM, Lim BT, Hendriks WD, Dijkshoorn L, van Boven CP. Methicillin-resistant staphylococcus aureus and acinetobacter baumannii: an unexpected difference in epidemiologic behavior. Am J Infect Control. 1998;26(6):544–551. doi:10.1053/ic.1998.v26.a84555
  • Marti E, Variatza E, Balcazar JL. The role of aquatic ecosystems as reservoirs of antibiotic resistance. Trends Microbiol. 2014;22(1):36–41. doi:10.1016/j.tim.2013.11.001
  • Meschiari M, Lopez-Lozano JM, Di Pilato V, et al. A five-component infection control bundle to permanently eliminate a carbapenem-resistant acinetobacter baumannii spreading in an intensive care unit. Antimicrob Resist Infect Control. 2021;10(1):123. doi:10.1186/s13756-021-00990-z
  • Bian X, Liu X, Zhang X, et al. Epidemiological and genomic characteristics of acinetobacter baumannii from different infection sites using comparative genomics. BMC Genomics. 2021;22(1):530. doi:10.1186/s12864-021-07842-5
  • Jiang M, Liu L, Ma Y, et al. Molecular epidemiology of multi-drug resistant acinetobacter baumannii isolated in Shandong, China. Front Microbiol. 2016;7:1687. doi:10.3389/fmicb.2016.01687
  • Deng M, Zhu MH, Li JJ, et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother. 2014;58(1):297–303. doi:10.1128/AAC.01727-13
  • Chen Y, Gao J, Zhang H, Ying C. Spread of the blaoxa-23-containing tn2008 in carbapenem-resistant acinetobacter baumannii isolates grouped in cc92 from China. Front Microbiol. 2017;8:163. doi:10.3389/fmicb.2017.00163
  • Lerner A, Adler A, Abu-Hanna J, Meitus I, Navon-Venezia S, Carmeli Y. Environmental contamination by carbapenem-resistant Enterobacteriaceae. J Clin Microbiol. 2013;51(1):177–181. doi:10.1128/JCM.01992-12
  • Yan Z, Zhou Y, Du M, et al. Prospective investigation of carbapenem-resistant Klebsiella pneumonia transmission among the staff, environment and patients in five major intensive care units, Beijing. J Hosp Infect. 2019;101(2):150–157. doi:10.1016/j.jhin.2018.11.019
  • World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter Baumannii and Pseudomonas Aeruginosa in Health Care Facilities. Geneva: World Health Organization; 2017.
  • Di Tella D, Tamburro M, Guerrizio G, Fanelli I, Sammarco ML, Ripabelli G. Molecular epidemiological insights into colistin-resistant and carbapenemases-producing clinical Klebsiella pneumoniae isolates. Infect Drug Resist. 2019;12:3783–3795. doi:10.2147/IDR.S226416
  • Lomonaco S, Verghese B, Gerner-Smidt P, et al. Novel epidemic clones of listeria monocytogenes, United States, 2011. Emerg Infect Dis. 2013;19(1):147–150. doi:10.3201/eid1901.121167
  • Xu H, Zhang W, Zhang K, et al. Characterization of salmonella serotypes prevalent in asymptomatic people and patients. BMC Infect Dis. 2021;21(1):632. doi:10.1186/s12879-021-06340-z
  • Xu Q, Fu Y, Zhao F, Jiang Y, Yu Y. Molecular characterization of carbapenem-resistant serratia marcescens clinical isolates in a tertiary hospital in Hangzhou, China. Infect Drug Resist. 2020;13:999–1008. doi:10.2147/IDR.S243197
  • Markogiannakis A, Fildisis G, Tsiplakou S, et al. Cross-transmission of multidrug-resistant acinetobacter baumannii clonal strains causing episodes of sepsis in a trauma intensive care unit. Infect Control Hosp Epidemiol. 2008;29(5):410–417. doi:10.1086/533545
  • Wheatley R, Diaz CJ, Kapel N, et al. Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute pseudomonas aeruginosa infection. Nat Commun. 2021;12(1):2460. doi:10.1038/s41467-021-22814-9
  • Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2):162. doi:10.3390/pharmaceutics13020162
  • Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10). doi:10.3390/antibiotics9100647
  • Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1):31. doi:10.3390/pharmaceutics14010031
  • Wanla W, Katip W, Supakul S, Apiwatnakorn P, Khamsarn S. Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation. Int J Gen Med. 2017;10:443–449. doi:10.2147/IJGM.S145133
  • Chen W. Host innate immune responses to acinetobacter baumannii infection. Front Cell Infect Microbiol. 2020;10:486. doi:10.3389/fcimb.2020.00486